1-5 of 5
Erin G. Reid, MD MS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1755.
https://doi.org/10.1182/blood-2019-131498
Published: 2019
Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Paul G. Rubinstein, MD, Page C. Moore, PhD, Milan Bimali, PhD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Michelle Rudek, PharmD, PhD, Lee Ratner, MD PhD, Richard F. Ambinder, MD, David H. Henry, MD, Stefan K. Barta, MD MRCP, MS, Herve Ghesquieres, MD PhD, Paul Coppo, MD PhD, Pierre Delobel, MD, Francois Boue, MD PhD, Lionel Galicier, MD, Juan Carlos Ramos, MD BS, Erin G. Reid, MD MS, Elad Sharon, MD MPH, Nicolas Mounier, MD, Caroline Besson, MD PhD, Ariela Noy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 130.
https://doi.org/10.1182/blood-2019-126787
Published: 2019
Journal Articles

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Krish Patel, MD, Jean-Marie Michot, MD, Asher A. Chanan-Khan, MD, Gilles A. Salles, MD PhD, Guillaume Cartron, MD PhD, Frederic Peyrade, MD, Reda Bouabdallah, Erin G. Reid, MD MS, Sheeba K. Thomas, MD, William G. Wierda, MD PhD, David Liebowitz, MD, John M. Pagel, MD PhD DSc, Vincent Ribrag, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, Thomas Ly, PhD, Tycel J. Phillips, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4079.
https://doi.org/10.1182/blood-2019-128564
Published: 2019
Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1588.
https://doi.org/10.1182/blood-2019-129687
Published: 2019
Journal Articles

PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study

Ida Wong-Sefidan, MD, Michelle Byrtek, PhD, Xiaolei Zhou, MS, Jonathan W. Friedberg, MD, Christopher Flowers, MD, Brian K Link, MD, Andrew D. Zelenetz, MD, PhD, Keith L Dawson, DNP, RN, Erin G. Reid, MD, MS
Journal: Blood
Blood (2013) 122 (21): 4245.
https://doi.org/10.1182/blood.V122.21.4245.4245
Published: 2013